BioNTech SE annual ebitda
2017
2018
2019
2020
2021
2022
2023
2024
2025
BioNTech SE EBITDA Growth & History (BNTX)
BioNTech SE's calculated EBITDA was −€1.02B for fiscal 2025.
View full BioNTech SE company overviewBioNTech SE annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −€1.02B | −€5.8M | — |
| 2024 | 2024-12-31 | −€1.02B | −€1.89B | — |
| 2023 | 2023-12-31 | €873.8M | −€11.89B | −93.16% |
| 2022 | 2022-12-31 | €12.77B | −€2.59B | −16.88% |
| 2021 | 2021-12-31 | €15.36B | €15.40B | — |
| 2020 | 2020-12-31 | −€43.7M | €103.9M | — |
| 2019 | 2019-12-31 | −€147.6M | −€115.7M | — |
| 2018 | 2018-12-31 | −€31.9M | €18.9M | — |
| 2017 | 2017-12-31 | −€50.7M | — | — |
BioNTech SE quarterly ebitda
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −€589.1M | −€241.1M | — |
| Q1 2026 | 2026-03-31 | −€442.8M | — | — |
| Q4 2025 | 2025-12-31 | −€511.6M | — | — |
| Q3 2025 | 2025-09-30 | €778.1M | — | — |
| Q2 2025 | 2025-06-30 | −€348.0M | — | — |
BioNTech SE ebitda trends
Over the last five fiscal years, BioNTech SE's ebitda decreased from −€43.7M to −€1.02B, a change of −€978.4M. The latest reported quarter, Q2 2026, shows −€589.1M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BioNTech SE source filings ↗Community posts
BioNTech reports longer survival in exploratory lung-cancer trial stage
BioNTech ($BNTX) and OncoC4 reported updated results for gotistobart in previously treated advanced squamous non-small cell lung cancer. Median overall survival reached 18.5 months versus 10 months with docetaxel in the non-pivotal first st ...
